Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Finite-Lived Intangible Assets by Quarter
Finite-Lived Intangible Assets — Net carrying amount ($M) ($M)
Pfizer Finite-Lived Intangible Assets: $29,273M in Q2 2026, down 14.0% from a year earlier.
Latest, Q2 2026
29,273
Period ended Jun 28, 2026
Change on a year earlier
-14.0%
34,028 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
45
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Goodwill & Other Intangible Assets Footnote.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Finite-Lived Intangible Assets — Net carrying amount ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 29,273 | -14.0% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 30,918 | -10.7% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 31,510 | -12.1% | Form 10-Q (filed 2026-08-04) ↗ |
| Q3 2025 | Sep 28, 2025 | 33,513 | -10.2% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 34,028 | -11.8% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 34,622 | -13.2% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 35,848 | -10.6% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 29, 2024 | 37,340 | +34.2% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 38,594 | +33.0% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 39,899 | +36.9% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 40,116 | +32.8% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Oct 1, 2023 | 27,830 | +50.3% | Form 10-Q (filed 2023-11-08) ↗ |
| Q2 2023 | Jul 2, 2023 | 29,011 | +50.8% | Form 10-Q (filed 2023-08-09) ↗ |
| Q1 2023 | Apr 2, 2023 | 29,141 | +46.5% | Form 10-Q (filed 2023-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 30,215 | +45.9% | Form 10-K (filed 2024-02-22) ↗ |
| Q3 2022 | Oct 2, 2022 | 18,522 | -15.1% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jul 3, 2022 | 19,236 | -15.6% | Form 10-Q (filed 2022-08-10) ↗ |
| Q1 2022 | Apr 3, 2022 | 19,894 | -15.1% | Form 10-Q (filed 2022-05-11) ↗ |
| Q4 2021 | Dec 31, 2021 | 20,714 | -12.8% | Form 10-K (filed 2023-02-23) ↗ |
| Q3 2021 | Oct 3, 2021 | 21,807 | -13.3% | Form 10-Q (filed 2021-11-12) ↗ |
| Q2 2021 | Jul 4, 2021 | 22,789 | -14.0% | Form 10-Q (filed 2021-08-12) ↗ |
| Q1 2021 | Apr 4, 2021 | 23,439 | -8.0% | Form 10-Q (filed 2021-05-13) ↗ |
| Q4 2020 | Dec 31, 2020 | 23,762 | -9.0% | Form 10-K (filed 2022-02-24) ↗ |
| Q3 2020 | Sep 27, 2020 | 25,142 | -16.1% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 28, 2020 | 26,509 | -8.8% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 29, 2020 | 25,482 | -15.0% | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 26,117 | -15.9% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 29, 2019 | 29,972 | -16.8% | Form 10-Q (filed 2019-11-07) ↗ |
| Q2 2019 | Jun 30, 2019 | 29,070 | -15.7% | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 29,963 | -15.7% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 31,045 | -15.1% | Form 10-K (filed 2020-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 36,012 | -3.9% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jul 1, 2018 | 34,494 | -11.6% | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Apr 1, 2018 | 35,537 | -11.2% | Form 10-Q (filed 2018-05-10) ↗ |
| Q4 2017 | Dec 31, 2017 | 36,562 | +2.5% | Form 10-K (filed 2019-02-28) ↗ |
| Q3 2017 | Oct 1, 2017 | 37,492 | +2.0% | SEC Filing ↗ |
| Q2 2017 | Jul 2, 2017 | 39,033 | +28.3% | SEC Filing ↗ |
| Q1 2017 | Apr 2, 2017 | 40,009 | +26.9% | SEC Filing ↗ |
| Q4 2016 | Dec 31, 2016 | 35,664 | +10.9% | Form 10-K (filed 2018-02-22) ↗ |
| Q3 2016 | Oct 2, 2016 | 36,750 | +5.7% | SEC Filing ↗ |
| Q2 2016 | Jul 3, 2016 | 30,425 | +18.0% | SEC Filing ↗ |
| Q1 2016 | Apr 3, 2016 | 31,530 | +18.1% | SEC Filing ↗ |
| Q4 2015 | Dec 31, 2015 | 32,165 | – | Form 10-K (filed 2017-02-23) ↗ |
| Q3 2015 | Sep 27, 2015 | 34,775 | – | SEC Filing ↗ |
| Q2 2015 | Jun 28, 2015 | 25,782 | – | SEC Filing ↗ |
| Q1 2015 | Mar 29, 2015 | 26,694 | – | SEC Filing ↗ |
Breakdown
What makes up finite-Lived Intangible Assets
- Finite-lived intangible assets — Gross carrying amount ($M)104,198 · Q2 2026
- Finite-lived intangible assets — Accumulated amortization ($M)74,925 · Q2 2026
- Developed technology rights — Net carrying amount ($M)28,287 · Q2 2026
- Brands — Finite-lived net carrying amount ($M)0 · Q2 2026
- Licensing agreements & other — Net carrying amount ($M)986 · Q2 2026
- Indefinite-Lived Intangible Assets (IPR&D & Brands) — Carrying amount ($M)17,780 · Q2 2026
- In-Process R&D (IPR&D) — Indefinite-lived carrying amount ($M)17,320 · Q2 2026
- Estimated future intangible amortization — Year 1 ($M)–
- Estimated future intangible amortization — Year 2 ($M)–
- Estimated future intangible amortization — Year 3 ($M)–
- Estimated future intangible amortization — Year 4 ($M)–
- Estimated future intangible amortization — Year 5 ($M)–
Cite this data
StockData. (2026). Pfizer Finite-Lived Intangible Assets ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/intang-net-tot
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.